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Abstract The early diagnosis of breast cancer in potential-
ly curable stages improves prognosis and consecutively
reduces mortality of breast cancer patients. Established
screening programs have an unfavorable connotation due to
significant rates of false negative as well as false positive
results leading to overdiagnosis and overtherapy. The
combination of a non-invasive breast-cancer-suspectabil-
ity-biomarker with established clinical diagnostics could
help to increase the acceptance of population based breast
cancer screening programs by creating an individual risk
profile, which is irrespective of mammography quality and
interpretation. Recently, non-invasive proteomic biomarkers
obtained from blood, saliva or nipple aspiration fluid have
been extensively investigated and might play a future role
in the personalized management of breast cancer screening.
A simple, robust and inexpensive, non-invasive test for
screening and diagnosis could easily be performed in every
medical practice leading to an affordable, high-throughput
instrument. This review describes recently investigated
proteomic screening biomarkers that could improve the
early diagnosis of breast cancer in the following years.
Keywords Breast cancer . Proteomics . Personalized
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Introduction
Breast cancer is the most commonly diagnosed type of
cancer in women and is responsible for 15% of cancer
related deaths in the United States [1]. Up to now clinical
breast examination, imaging by mammography as well as
tumor biopsy are the only recommended methods for breast
cancer screening in the non-high risk population [2]. A non-
invasive test for the early diagnosis of breast cancer would
be an efficient step into personalized breast cancer
screening and could significantly improve breast cancer
survival by bringing the time of diagnosis at an earlier and
therefore still curable stage [3, 4]. As an early diagnosis is
the key for the successful treatment of breast cancer, much
effort has been made to develop non-invasive biomarkers
for the detection of early-stage breast cancer. But so far
there is no reliable non-invasive test available for the
clinical routine [2, 5].
In this review we would like to give an overview of
investigated proteomic screening biomarkers in breast
cancer research that could gain success in non-invasive
breast cancer screening in the following years.
Non-invasive proteomics
Protein profiling-methods
As we know, cancer arises from genetic changes, by which
numerous cellular processes such as growth regulation,
proliferation and apoptosis are altered [6, 7]. Consequently,
first approaches towards cancer-specific biomarkers were
based on Genomics and Transcriptomics to get further
insights into the genetic basis of cancer development [8–
11]. In the process of developing an individual risk profile
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for the development of breast cancer two breast cancer
susceptibility genes BRCA1 and BRCA2 were identified in
families with strong patterns of breast cancer [8, 11]. These
two genes are considered to be tumor suppressors and can
be found in all women as well as men. Women carrying a
mutation in either BRCA1 or BRCA2 are in significantly
higher risk of developing breast cancer or ovarian cancer
[12]. Thus genetic testing for alterations in BRCA1 and
BRCA2 can be used for predicting the individual risk of
breast cancer development in patients with familial anam-
nesis of hereditary breast cancer. Nevertheless, there are
major concerns regarding the use of BRCA1 and BRCA2
for genetic testing due to the variability of the eventual
onset of breast cancer as well as the final outcome. In
addition, women with familial risk without any mutations
in BRCA1 or BRCA2 are still at risk of developing breast
cancer after a negative testing for one of these genes.
Hence, both—negative as well as positive results—may
lead to mental distress and concerns regarding further
management [13–15]. Alternative splicing of mRNA as
well as proteins in combination with the multiplicity of
post-translational alterations such as phosphorylation, ubiq-
uitination or nitration explain why one single gene code for
different protein species [16, 17]. Thus, Genetics by itself
shows just an incomplete pattern of cancer development,
whereas Proteomics reflects the genetic program of each
cell as well as its final influence on the cellular physiology
in a more dynamic way [18, 19].
The quest for screening biomarkers in cancer was
initially based on two-dimensional gel electrophoresis
(Fig. 1) [20]. Thereby specific protein fingerprints in
malignant conditions are detected by their apparent molec-
ular mass and isoelectric point. For protein detection the
electrophoretically separated polypeptides are visualized by
sensitive staining methods such as silver staining. In a
further step the patterns of patients' samples and healthy
controls are screened for differences in protein patterns. The
spots of interest are excised from the gel, subjected to
protease digestion by what peptide fragments can be
examined in further analyses. Nevertheless, it is a time
consuming process that is difficult to automate and to
reproduce. Furthermore, it cannot adequately resolve the
large number of protein modifications within a tumor
sample.
Later on, advances in analytical technologies regarding
mass spectroscopy (MS) facilitated large-scale proteomic
analyses (Fig. 2) [21]. MS measures the mass to charge
ratio (m/z) of ionized proteins as they travel through an
electric or a magnetic field. Proteins are analyzed and
identified based on unique spectrometric signatures, which
reveals even structural features such as phosphorylation or
methylation.
Blood-based protein profiling
Reflecting the physiological and pathological status of the
human body in combination with its easy collection and
availability blood represents the most extensively studied
substance in the search of cancer biomarkers [22]. Specific
tumor-secreted proteins in conjunction with cancer related
patterns of digested tissue and plasma proteins make blood
the ideal source for proteomic analyses [18, 23].
Numerous serum- and plasma-based SELDI-TOF MS
and MALDI-TOF MS analyses were performed during the
last years to differentiate between breast cancer patients,
benign disease and healthy controls [24–27]. Each study
described specific patterns of protein peaks, whereas all of
them kept structurally unidentified and their validation in
an independent sample set is still outstanding. Contrariwise,
Li et al. screened the serum of 103 stage I–III breast cancer
patients, 25 benign controls as well as 41 healthy women
and verified two increased peaks (8.1 kDa, 8.9 kDa) as well
as one decreased peak (4.3 kDa) in the serum of breast
cancer patients which have been structurally identified as
the C-terminal truncated form of complement component
C3a (CtC3a, 8.1 kDa), complement component C3a itself
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Fig. 1 Protein identification by two-dimensional gel electrophoresis
(2D-PAGE). A: Protein extraction of patients' samples and healthy
controls. B: By isoelectric focusing (IEF) proteins are separated on
their isoelectric point (pI) in a strong electric field using stripes with
an immobilized pH gradient (IPG-Stripe). C: After IEF an electric
potential is applied to the IPG-Stripe at a 90 degree angle from the
first field and proteins are separated by sodium dodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The gel acts as a
molecular sieve by separating the proteins on the basis of their relative
molecular mass. D: Proteins are visualized by sensitive staining
methods such as silver staining
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(8.9 kDa) and a fragment of inter-alpha-trypsin inhibitor
heavy chain H4 (ITIH4, 4.3 kDa) [28, 29]. In a further
independent sample set only the C-terminal truncated form
of complement component C3a (8.1 kDa) and complement
component C3a (8.9 kDa) could be verified, whereas the
8.1 kDa-fragment also lost its significance in further
validation [29–31]. In comparable studies the decreased
ITIH4-fragment at 4.3 kDa was found to be increased in the
serum of breast cancer patients or even lost its ability to
distinguish between cancer patients and healthy controls
[32–34]. Due to the inhomogeneous results regarding
ITIH4 and the C3-complement components described
above, which have recently been reconfirmed to be up-
regulated in breast cancer patients, the diagnostic strength
of these markers can not be finally evaluated yet [35]. Fan
et al. described also a down-regulated candidate protein
(6.6 kDa), which was identified as apolipoprotein C-1
(APO-C1) that might play a certain role in breast cancer
carcinogenesis [35]. Further candidate biomarkers of the
lipoprotein-group (APO A-IV) had also been described by
Villanueva et al. before, whereas these findings as well as
the diagnostic power of further candidate markers such as
fibrinogen alpha, bradykinin, factor XIII or transthyretin
have to be validated in larger studies before their future
clinical implementation [34]. In a pathology-specific blood
proteome analysis by Braun et al. expression patterns of
circulating leucokytes were investigated in breast cancer
patients, patients with benign tumors and healthy controls
[36]. Performing protein mapping this group demonstrated
significant alterations in the repertoire of microfilamental
network-associated proteins in circulating leukocytes of
breast cancer patients compared to healthy controls:
Calgranulin A (S100), LyGDI (RhoGDIβ), RhoA and
profilin 1. Investigating cellular subfractions by two-
dimensional gel electrophoresis (2D-PAGE), nuclear matrix
proteins (NMP) have been shown to be cell and cancer
specific [37–40]. Hence, circulating NMP are ideal candi-
dates for non-invasive cancer diagnosis in several cancer
entities [41–43]. Unlike established protocols of separating
NMP by two-dimensional gel electrophoresis, NMP66
(28.3 kDa) was found to be specific for breast cancer by a
serum proteomic screening strategy using SELDI-TOF MS
[44]. But up to now NMP66 did not make its way to
clinical routine. Based on our expertise with CCSA-2 in the
development of a serum-based immunoassay in colon
cancer we are investigating the use of NMP in breast
Fig. 2 Schematic demonstration of MALDI- and SELDI-TOF MS
(adapted from [20]). A1–A3: Performing matrix-assisted laser desorp-
tion/ionization-time of flight mass spectrometry (MALDI-TOF MS)
the samples are fractionated off-line using chromatographic beads. An
energy absorbing matrix e.g. cinnamic acid is added to the fractionated
samples and this mix is applicated to an inert plate for laser
desorption/ionization in a time of flight (TOF) mass analyzer (C).
B1–B3: For surface-enhanced laser desorption/ionization-time of
flight mass spectrometry (SELDI-TOF MS) the sample is loaded onto
a protein-selective array with a hydrophilic, hydrophobic, cationic,
anionic or immobilized-metal affinity capture moiety in an appropriate
binding buffer. The sample is purified by one or more washing steps
and the bound proteins are treated with an energy-absorbing matrix
such as cinnamic acid for desorption/ionization by laser in a TOF
mass analyzer (C). C: The MALDI target plate or SELDI array is
inserted into the analyzer, where bound proteins are treated with laser
irradiation for desorption and ionization. Owing to the electric field,
they are accelerated through a TOF-analyzer and separated by a mass
per charge ratio (m/z): small proteins (c) migrate faster than multiply
charged (b) or large ones (a). D: In a resulting mass spectrum the m/z-
ratio is displayed on the x-axis, whereas the y-axis reflects the protein
abundance. Here, SELDI-TOF MS shows up-regulations in the serum
of breast cancer patients (BC) compared to healthy controls (HC) are
visible at m/z 3980, m/z 4292 and m/z 8939
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cancer by two-dimensional gel electrophoresis in an
ongoing study [43].
Diagnostic proteomics in nipple aspiration
Nipple fluid, that contains breast epithelial cells, is produced
in the breast ducts and can be collected by vacuum aspiration
or ductal lavage. Based on the idea that the concentrated
source of proteins from breast cancer ducts might be better
able to identify tumor-specific protein patterns, attention has
been paid to the proteomic analysis of nipple aspiration fluid
(NAF) and ductal lavage fluid (DLF). Performing SELDI-
TOFMS of 114 NAF-samples obtained from 27 breast cancer
patients and 87 healthy controls Sauter et al. defined a
11.8 kDa protein that appeared to be specific for breast cancer
patients [45]. Pawlik et al. employed the use of SELDI-TOF
MS to NAF in 23 women with stage I and II breast cancer to
compare them to 5 healthy volunteers [46]. In this study 17
peaks were overexpressed in cancer-bearing breasts com-
pared to breasts of healthy controls (p<0.0005). When
spectra from the nontumor-bearing breasts of breast cancer
patients were compared with spectra from breasts of healthy
controls, two distinct peaks were noted to be overexpressed
in breast cancer patients and one peak was underexpressed
(p<0.0027). These results get support from Noble et al. who
found nine protein peaks to be significantly different
between the cancer-bearing breast compared with healthy
women as well as 10 peaks of the contralateral healthy breast
and healthy women (p<0.05) [47]. Performing two-
dimensional gel electrophoretic separation and MALDI-
TOF analysis in 20 NAF-samples of 10 breast cancer
patients and 10 healthy controls Alexander et al. distin-
guished between three peaks that were up-regulated in three
or more breast cancer patients [48]. These peaks were
identified as gross cystic disease fluid protein-15 (GCDFB-
15), apolipoprotein-D (apo-D) and alpha-1-acid glycoprotein
(AAG). For further validation 105 NAF-samples (52
cancerous and 53 controls) were analyzed by ELISA,
whereas GCDFB-15 levels were showed to be lower (p<
0.001) and AAG levels to be higher (p<0.001) in breast
cancer patients. Apo-D levels were not associated with breast
cancer in this control.
Based on recent findings of Suijkerbuijk et al., who
described the advantages of Oxytocin-supported nipple
aspiration affiliated with reduced discomfort (Fig. 3),
NAF might be a promising instrument for breast cancer
diagnosis and should be validated in further studies [49].
Salivary protein profiling
Saliva is the secretion of the salivary glands representing a
source of easily accessible body fluids. In 1999 the use of
saliva for diagnostic purposes has been demonstrated by the
detection of elevated levels of CA15.3 and c-erB-2 in breast
cancer patients [50]. Inspired by the absolute non-invasive
character as well as the ease of sample handling Steckfus et
al. investigated the feasibility of salivary protein profiling
for diagnostic purposes in breast cancer [51]. Using SELDI-
TOF MS five high molecular weight peaks were found to
be overexpressed in breast cancer patients compared to
healthy controls. Although these peaks were never struc-
turally identified this group was able to demonstrate the
potential use of saliva for breast cancer diagnosis. Recently,
the initial findings were supported by salivary protein
profiles that are unique to fibroadenoma and ductual
carcinoma in-situ of the breast [52].
Fig. 3 Discomfort of nipple aspiration in comparison with mammog-
raphy and breast feeding in a study on female healthy volunteers [48]
a b
Fig. 4 False-negative medio-
lateral oblique mammogram of
a 50 years old female patient in
routine breast cancer screening
(a). The additional Breast-MRI
(b) identifies two small enhanc-
ing foci (arrows). MR-guided
biopsy revealed multifocal
ductal invasive breast cancer
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Potential behind non-invasive diagnostic technologies
The early diagnosis of breast cancer in a potentially curable
stage improves the prognosis and consecutively reduces
mortality of breast cancer patients [3, 4]. The established
screening by breast examination and mammography is able to
detect breast cancer in early stages and has been shown to
reduce mortality [53, 54]. Nevertheless, screening by mam-
mography is controversially discussed due to significant rates
of false negative results (Fig. 4) as well as false positive
results leading to overdiagnosis and overtherapy [55].
Especially young women (<50 years) with high breast density
show low sensitivities in mammography, wherefore estab-
lished mammography screening programs are mainly
addressed to older patients (50–69 years) [56, 57]. Keeping
in mind that 1 of 5 breast cancers occurs in this non-screened
subgroup and these patients suffer from more aggressive and
fast growing forms of breast cancer the proposed non-invasive
screening biomarker would be of outstanding value [58, 59].
Thus it is necessary to implement a reliable non-invasive
test as a gatekeeper for further diagnostics among asymptom-
atic patients (Fig. 5). In a second step only patients with a
positive breast-cancer-suspectability-biomarker would re-
ceive further imaging or biopsy. Asymptomatic patients
showing a negative breast-cancer-suspectability-biomarker
are not in need of additional clinical diagnostics and are
spared uncertainties and anxiety due to ambiguous imaging
results. Table 1 summarizes candidate non-invasive proteo-
mic biomarkers that could improve the early diagnosis of
breast cancer in the following years.
Asymptomatic 



























Fig. 5 Flow-chart: Personalized Screening for breast cancer using a
screening biomarker as gatekeeper before further clinical diagnostics
Medium Biomarker Profiling method
Serum C3a SELDI-TOF MS
Serum CtC3a SELDI-TOF MS
Serum ITIH4 SELDI-TOF MS
Serum APO-C1 SELDI-TOF MS
Serum APO A-IV MALDI-TOF MS
Serum Fibrinogen alpha MALDI-TOF MS
Serum Bradykinin MALDI-TOF MS
Serum Factor XIII MALDI-TOF MS
Serum Transthyretin MALDI-TOF MS
Blood (Leukocytes) Calgranulin A 2D-PAGE, MALDI-TOF MS
Blood (Leukocytes) LyGDI (RhoGDIβ) 2D-PAGE, MALDI-TOF MS
Blood (Leukocytes) RhoA 2D-PAGE, MALDI-TOF MS
Blood (Leukocytes) Profilin 1 2D-PAGE, MALDI-TOF MS
Serum NMP66 SELDI-TOF MS
Nipple fluid 11.8 kDa peak (structurally unidentified) SELDI-TOF MS
Nipple fluid GCDFB-15 2D-PAGE, MALDI-TOF MS
Nipple fluid APO-D 2D-PAGE, MALDI-TOF MS
Nipple fluid AAG 2D-PAGE, MALDI-TOF MS
Saliva 18 kDa peak (structurally unidentified) SELDI-TOF MS
Saliva 113 kDa peak (structurally unidentified) SELDI-TOF MS
Saliva 170 kDa peak (structurally unidentified) SELDI-TOF MS
Saliva 228 kDa peak (structurally unidentified) SELDI-TOF MS
Saliva 287 kDa peak (structurally unidentified) SELDI-TOF MS
Table 1 Non-invasive Proteo-
mic biomarkers for breast can-
cer discussed in this review
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Clinical impact of predictive medicine in breast cancer
treatment
In a further step towards personalized medicine recent
biomarker developments regarding innate tumor character-
istics could contribute to a more individualized breast cancer
management. It has been shown that each tumor presents
unique characteristics with different outcomes, relapse and
responsiveness to therapy [60–62]. Traditionally, breast
cancer prognosis was determined by clinical as well as
histopathological features such as age, tumor size, lymph
node status, grading, hormone receptor status and Her2/neu
status [63–65]. Recently, these traditional factors have been
completed by multi gene expression tools like Mammaprint,
Oncotype DX or Rotterdam Signature that can be used to
predict the risk of recurrence or distant metastases in node-
negative disease [9, 10, 66–68]. In patients with newly
diagnosed node-negative breast cancer urokinase plasmino-
gen activator (uPA) and plasminogen activator inhibitor 1
(PAI-1) might be used for prognostic evaluation as well [69].
It has been shown that elevated levels of both factors, uPA
and PAI-1, in tumor tissue are associated with a higher risk
of recurrence and death, wherefore especially these patients
may benefit from adjuvant treatment [70–72]. Another target
of individualized breast cancer management should be
residing on predictive biomarkers determining the response
to certain adjuvant regimes in a particular patient. It is
known that Anthracycline-based treatment alone as well as
in combination with Taxanes shows significant benefits in
patients with lymph node-positive breast cancer and Her2/
neu-overexpression [73–75]. Further factors like Topoisomer-
ase II-overexpression, which suggests greater benefit from
Anthracycline-based chemotherapy, or low expression of
Microtubule-associated protein tau, which is associated with
increased chemosensitivity to Taxanes, are under ongoing
investigation [76–78]. Contrariwise, high levels of Tau
correlate with estrogen receptor (ER)-positive breast cancer
and may predict endocrine sensitivity in this subgroup of
patients [79]. Consequentially, an increased expression of
Microtubule-associated protein tau may define ER-positive
breast cancers with increased sensitivity to endocrine therapy,
whereas lower Tau levels may indicate better chemosensi-
tivity to Taxanes ER-positive breast cancer patients [80].
Outlook
Biomarkers that detect cancer, predict cancer outcome and
influence treatment choices will play a major role in the
future management of breast cancer. The proposed combi-
nation of an objective breast-cancer-suspectability-
biomarker with established clinical diagnostics could help
to increase the acceptance of population based breast cancer
screening programs by creating an individual risk profile,
which is irrespective of mammography quality and inter-
pretation. A simple, robust and inexpensive, non-invasive
test for screening and diagnosis could easily be performed
in every medical practice leading to an affordable, high-
throughput instrument. Recent technological improvements
to identify and characterize proteins by two-dimensional
gel-electrophoresis and mass spectroscopy in combination
with improved bioinformatical databases and analysis
software make Proteomics a powerful tool in the quest for
new tumor markers. Thus, outmost effort should be put into
the development, validation and clinical implementation of
reliable screening biomarkers.
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